overactive bladder articles & resources on Made-in-China.com

Urinary Incontinence Affects up to 13% of Australian Men

Feb 26, 2014

Urinary incontinence affects up to 13% of Australian men and up to 37% of Australian women. There are several types of urinary incontinence, and each has different treatment options. In the latest edition of Australian Prescriber, Shannon ...

Tags: Incontinence, Treatment Option, reducing symptom, bladder

AltheRx Pharmaceuticals Has Received a Notice of Allowance for Its Patent Application

Oct 21, 2013

US-based clinical development firm AltheRx Pharmaceuticals has received a notice of allowance for its patent application from the US Patent and Trademark Office (USPTO) for the use of solabegron in combination with antimuscarinics at both ...

Tags: Solabegron Combination Therapy, Oab Patients

Astellas Has Introduced Myrbetriq as Overactive Bladder Therapy in Canada

Apr 12, 2013

Astellas Pharma Canada has introduced Myrbetriq (mirabegron, extended-release tablets) as overactive bladder (OAB) therapy in Canada. Myrbetriq is indicated to treat OAB with symptoms of urge urinary incontinence, urgency and urinary ...

Tags: Astellas Pharma, Bladder Medication, Medicine

Botox or Oxytrol Patch OTC Maybe Not for Bladder Problems

Jan 30, 2013

If you suffer from overactive bladder you now have two new options: Botox injections (yes, the wrinkle-shrinking drug), and an over-the-counter version of the Oxytrol patch, which used to require a prescription. The Food and Drug ...

Tags: overactive bladder, Botox injections, healthcare, medical tips

Merck Has Received FDA Approval for an Over-The-Counter (OTC) Treatment

Jan 29, 2013

Merck has received FDA approval for an over-the-counter (OTC) treatment for overactive bladder (OAB) in women, Oxytrol for women. Various studies demonstrated a woman's ability to recognize OAB symptoms, understand vital safety ...

Tags: bladder OTC treatment, Merck, OAB symptoms

FDA Has Approved Allergan's Botox as Overactive Bladder Therapy for Adults

Jan 22, 2013

The USFDA has approved Allergan's Botox (onabotulinumtoxinA) as overactive bladder (OAB) therapy for adults who do not respond to or who cannot tolerate an anticholinergic medication. The approval was based on safety and efficacy data ...

Tags: FDA, Allergan overactive bladder, anticholinergic treatments

Positive Results Are Reported by Uroplasty From Tibial Nerve Stimulator Long-Term Study

Dec 18, 2012

Uroplasty has reported positive results from subcutaneous tibial nerve stimulator's nine-year follow-up study. The FDA-approved stimulator, Urgent PC neuromodulation system, is a minimally invasive device used for treating overactive ...

Tags: Uroplasty, Urgent PC neuromodulation system, minimally invasive device

AMS and Allergan Decide to Jointly Seek Approval for Botox Delivery Using Jettouch System

Dec 18, 2012

American Medical Systems (AMS), an Endo Health Solutions company, and Allergan have entered into an agreement to jointly develop and seek regulatory approval for the delivery of Botox (onabotulinumtoxinA) using the JetTouch system. ...

Tags: AMS, JetTouch system, medical application

CHMP of The EMA Has Recommended Astellas Pharma Europe's Betmigatm

Dec 4, 2012

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Astellas Pharma Europe's Betmigatm (mirabegron) for the symptomatic treatment of urgency, increased micturition frequency ...

Tags: symptomatic treatment of urgency, pharmaceutical product

Watson Laboratories Received FDA Approval for Its ANDA of Trospium Chloride Capsules

Dec 4, 2012

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received FDA approval for its abbreviated new drug application (ANDA) of Trospium Chloride Extended-release Capsules. Watson anticipates beginning the shipment of the ...

Tags: FDA, Trospium Chloride Extended-release Capsules, pharmaceutical product

Pfizer Canada Has Introduced Toviaz

Nov 29, 2012

Pfizer Canada has introduced Toviaz (fesoterodine fumarate extended release tablets) that is indicated for the treatment of patients with overactive bladder (OAB) with symptoms of urinary frequency, urgency, or urge incontinence, or any ...

Tags: Pfizer Canada, Toviaz, overactive bladder, OAB

Teva UK Has Launched Generic Tolterodine 1mg and 2mg Film-Coated Tablets

Nov 29, 2012

Teva UK has launched generic Tolterodine 1mg and 2mg film-coated tablets, and Tolterodine XL (Mariosea XL) 4mg capsules. Tolterodine is a generic version of Detrusitol (tolterodine) while Tolterodine XL (Mariosea XL) is a generic version ...

Tags: generic tolterodine, medicines, overactive bladder syndrome

Mylan Have Signed a Settlement Agreement with Pfizer

Nov 29, 2012

Mylan and its subsidiary, Mylan Pharmaceuticals, have signed a settlement agreement with Pfizer, Pharmacia & Upjohn Company and Pfizer Health related to Detrol LA patent litigation. The litigation is related to Mylan Pharmaceuticals' ...

Tags: Detrol LA patent litigation, drug application

Antares and Watson Pharmaceuticals Have Introduced Gelnique 3% Gel 3%

Nov 28, 2012

Antares Pharma and Watson Pharmaceuticals have introduced Gelnique 3% (oxybutynin) gel 3%, for the treatment of overactive bladder (OAB). The product is available in a metered pump dispenser and is delivered transdermally, resulting in a ...

Tags: Gelnique 3%, treatment of overactive bladder, urology

Myrbetriq Is a Once Daily Oral Beta-3 Adrenergic Agonist Discovered and Developed

Jun 4, 2012

Astellas Pharma has gained FDA approval for Myrbetriq (mirabegron) extended-release tablets for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. Myrbetriq is a once ...

Tags: FDA approval, pharmaceutical product, oral OAB treatment

overactive bladder

Related Products